DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy.

A. V. Hill; W. Reece; P. Gothard; V. Moorthy; M. Roberts; K. Flanagan; M. Plebanski; C. Hannan; J. T. Hu; R. Anderson; P. Degano; J. Schneider; E. Prieur; E. Sheu; S. C. Gilbert

DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy.

A. V. Hill, W. Reece, P. Gothard, V. Moorthy, M. Roberts, K. Flanagan, M. Plebanski, C. Hannan, J. T. Hu, R. Anderson, P. Degano, J. Schneider, E. Prieur, E. Sheu, S. C. Gilbert

Research output: Contribution to journal › Review Article › Research › peer-review

36 Citations (Scopus)

Abstract

A generic approach to inducing high level CD8+ T cell responses would be of value for prophylactic and therapeutic immunisation against several infectious diseases. However, it has been very difficult to achieve such immune responses using available vaccination strategies. Malaria is one of several diseases against which a new generation of better CD8+ T cell-inducing vaccines might be useful and is unusual in that it allows assessment of vaccine efficacy in small numbers of volunteers in carefully controlled challenge studies. Here we review the identification of a heterologous prime-boost regime using DNA priming and recombinant modified vaccinia Ankara (MVA) boosting that induces high level T cell responses in both mice and non-human primates. Clinical trials to determine whether this prime-boost approach is immunogenic in humans are in progress.

Original language	English
Pages (from-to)	171-179
Number of pages	9
Journal	Developments in Biologicals
Volume	104
Publication status	Published - 2000
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{08982e5d8b704c558bf76d93a69d5238,

title = "DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy.",

abstract = "A generic approach to inducing high level CD8+ T cell responses would be of value for prophylactic and therapeutic immunisation against several infectious diseases. However, it has been very difficult to achieve such immune responses using available vaccination strategies. Malaria is one of several diseases against which a new generation of better CD8+ T cell-inducing vaccines might be useful and is unusual in that it allows assessment of vaccine efficacy in small numbers of volunteers in carefully controlled challenge studies. Here we review the identification of a heterologous prime-boost regime using DNA priming and recombinant modified vaccinia Ankara (MVA) boosting that induces high level T cell responses in both mice and non-human primates. Clinical trials to determine whether this prime-boost approach is immunogenic in humans are in progress.",

author = "Hill, {A. V.} and W. Reece and P. Gothard and V. Moorthy and M. Roberts and K. Flanagan and M. Plebanski and C. Hannan and Hu, {J. T.} and R. Anderson and P. Degano and J. Schneider and E. Prieur and E. Sheu and Gilbert, {S. C.}",

year = "2000",

language = "English",

volume = "104",

pages = "171--179",

journal = "Developments in Biologicals",

issn = "1424-6074",

publisher = "S Karger AG",

}

TY - JOUR

T1 - DNA-based vaccines for malaria

T2 - a heterologous prime-boost immunisation strategy.

AU - Hill, A. V.

AU - Reece, W.

AU - Gothard, P.

AU - Moorthy, V.

AU - Roberts, M.

AU - Flanagan, K.

AU - Plebanski, M.

AU - Hannan, C.

AU - Hu, J. T.

AU - Anderson, R.

AU - Degano, P.

AU - Schneider, J.

AU - Prieur, E.

AU - Sheu, E.

AU - Gilbert, S. C.

PY - 2000

Y1 - 2000

N2 - A generic approach to inducing high level CD8+ T cell responses would be of value for prophylactic and therapeutic immunisation against several infectious diseases. However, it has been very difficult to achieve such immune responses using available vaccination strategies. Malaria is one of several diseases against which a new generation of better CD8+ T cell-inducing vaccines might be useful and is unusual in that it allows assessment of vaccine efficacy in small numbers of volunteers in carefully controlled challenge studies. Here we review the identification of a heterologous prime-boost regime using DNA priming and recombinant modified vaccinia Ankara (MVA) boosting that induces high level T cell responses in both mice and non-human primates. Clinical trials to determine whether this prime-boost approach is immunogenic in humans are in progress.

AB - A generic approach to inducing high level CD8+ T cell responses would be of value for prophylactic and therapeutic immunisation against several infectious diseases. However, it has been very difficult to achieve such immune responses using available vaccination strategies. Malaria is one of several diseases against which a new generation of better CD8+ T cell-inducing vaccines might be useful and is unusual in that it allows assessment of vaccine efficacy in small numbers of volunteers in carefully controlled challenge studies. Here we review the identification of a heterologous prime-boost regime using DNA priming and recombinant modified vaccinia Ankara (MVA) boosting that induces high level T cell responses in both mice and non-human primates. Clinical trials to determine whether this prime-boost approach is immunogenic in humans are in progress.

UR - http://www.scopus.com/inward/record.url?scp=0034578149&partnerID=8YFLogxK

M3 - Review Article

C2 - 11713817

AN - SCOPUS:0034578149

SN - 1424-6074

VL - 104

SP - 171

EP - 179

JO - Developments in Biologicals

JF - Developments in Biologicals

ER -

DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy.

Abstract

UN SDGs

Other files and links

Cite this